AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01044745 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT01044745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: graft-versus-tumor induction therapy
Description: Undergo graft-versus-tumor induction therapy
Study NCT01044745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immunosuppressive therapy
Description: Undergo immunosuppressive therapy
Study NCT03036683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation will be administered for 20 minutes using a CE approved stimulator (NeuroConn, Ilmenau, Germany).
Study NCT02434328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab ophthalmic solution
Description: Ophthalmic solution for IVT injection administered as a 6 mg/50 µL dose
Study NCT02434328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept ophthalmic solution
Description: Ophthalmic solution for IVT injection administered as a 2 mg/50 µL dose
Study NCT00358410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW679769 oral tablets
Description: 2x GW679769 60mg tablets
Study NCT00358410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablets to match experimental intervention
Study NCT01291771 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire
Description: The guide is placed in the distal segment of the coronary artery to measure instantaneously distal pressure and temperature with a tip sensor. Proximal pressure and temperature are being measured from the probe used to catheterize the coronary vessel and from the shaft of the guide. After basal measurement, intracoronary injection of 150µg of adenosine is performed to induce peripheral vasodilatation leading to hyperaemia in the vessel. Additional injection of 3mL 0.9% saline bolus at room temperature at the time of hyperaemia is performed to calculate CFR from transit mean time. FFR and CFR are being recorded at the time of hyperaemia. Subsequently IMR is being calculated from distal pressure and transit mean time. The measurements will be performed in the LAD, circumflex and right coronary arteries.
Study NCT01291771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire
Description: The guide is placed in the distal segment of the coronary artery to measure instantaneously distal pressure and temperature with a tip sensor. Proximal pressure and temperature are being measured from the probe used to catheterize the coronary vessel and from the shaft of the guide. After basal measurement, intracoronary injection of 150µg of adenosine is performed to induce peripheral vasodilatation leading to hyperaemia in the vessel. Additional injection of 3mL 0.9% saline bolus at room temperature at the time of hyperaemia is performed to calculate CFR from transit mean time. FFR and CFR are being recorded at the time of hyperaemia. Subsequently IMR is being calculated from distal pressure and transit mean time. The measurements will be performed in the LAD, circumflex and right coronary arteries.
Study NCT04595422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Undergo training consisting of a 60-minute educational session
Study NCT04595422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive lung cancer screening educational materials
Study NCT04595422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT04595422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT01755767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Tivantinib tablets
Study NCT01755767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study NCT01023048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preimplantation diagnosis
Description: genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)
Study NCT00186940 — intervention group
Intervention type: DRUG
Intervention: Rasburicase
Description: Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.
Study NCT03036683 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
Study NCT02961933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apneic oxygenation
Description: Nasal cannula apneic oxygenation
Study NCT02421224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
Study NCT02961933 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-oxgenation with NRB, NIPPV, BVM
Description: Pre-oxygenation with non-rebreather mask, non-invasive positive pressure ventilation, or bag-valve mask
Study NCT04388319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Zonisamide (100 mg/daily) for 12 weeks.
Study NCT04388319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 12 weeks.
Study NCT04388319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Halo G6 e-cigarette
Description: G6 e-cigarette for ad libitum use for two weeks prior to complete switch day.
Study NCT00326183 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAQTA®
Description: 0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment.
Study NCT00326183 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ProQuad
Description: 0.5 ml injection ProQuad; 2nd 0.5 ml injection ProQuad®. 24 week period of treatment.
Study NCT03803475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 labeled PSMA-11
Description: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if there is presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
Study NCT03803475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography-computed tomography (PET/CT)
Description: Positron emission tomography-computed tomography (PET/CT) is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography (PET) scanner and an x-ray computed tomography (CT) scanner, to acquire sequential images from both devices in the same session
Study NCT03803475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography-magnetic resonance imaging (PET/MRI)
Description: A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan in a single session
Study NCT04348565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Care Programme
Description: 20-week Diabetes Care Programme consists of three Diabetes Conversation Map sessions in 8 weeks with 3-4 weeks intervals, then two teleconsultations at week 12th and week 16th
Study NCT03379857 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Drug urinal test
Description: Non Applicable
Study NCT00559845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 600 milligrams per meter squared (mg/m\^2) as an intravenous (i.v.) bolus over ≤15 minutes every 3 weeks for 4 cycles.
Study NCT04140643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozonated water delivering device effects on the oral health of pregnant women
Description: Oral Hygiene instructions and use of an ozonated water delivering device in pregnant women for a period of 75 days.
Study NCT04140643 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene instructions
Description: Oral Hygiene instructions
Study NCT00559845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidoxorubicin
Description: 90 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
Study NCT00559845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
Study NCT00559845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered at 80 mg/m\^2 i.v. over 1 hour weekly for 12 weeks.
Study NCT00559845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was administered at 10 milligrams per kilogram (mg/kg) i.v. every 2 weeks for 6 cycles.
Study NCT02309879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate infusion
Description: Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
Study NCT02309879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate and Lidocaine infusion
Description: Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
Study NCT02618889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: All participating subjects will start a 12-week CBT treatment program. These consist of weekly 1-hour CBT sessions led by a cognitive therapist. Assessments will be repeated at week 16. All PsyD subjects will undergo a 15-minute, structured diagnostic interview (Mini International Neuropsychiatric Interview (MINI)) developed to screen for axis I DSM-IV and ICD-10 psychiatric disorders. We will also use two clinician-rated instruments to assess comorbid psychopathology in PsyD patients, the 17-item Hamilton Depression Rating Scale (HAM-D), to evaluate for depressed mood, vegetative and cognitive symptoms of depression; and the 14-item Hamilton Anxiety Rating Scale (HAM-A) to evaluate psychic and somatic anxiety. These scales will be administered as part of a structured interview.
Study NCT02618889 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT
Description: All participating subjects will start a 12-week CBT treatment program. These consist of weekly 1-hour CBT sessions led by a cognitive therapist. Assessments will be repeated at week 16. All PsyD subjects will undergo a 15-minute, structured diagnostic interview (Mini International Neuropsychiatric Interview (MINI)) developed to screen for axis I DSM-IV and ICD-10 psychiatric disorders. We will also use two clinician-rated instruments to assess comorbid psychopathology in PsyD patients, the 17-item Hamilton Depression Rating Scale (HAM-D), to evaluate for depressed mood, vegetative and cognitive symptoms of depression; and the 14-item Hamilton Anxiety Rating Scale (HAM-A) to evaluate psychic and somatic anxiety. These scales will be administered as part of a structured interview.
Study NCT03745170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Weight\<60Kg: 3mg/kg Q3W Weignt>=60Kg:200 mg Q3W on Day 1 by IV infusion
Study NCT04219631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: expiration mouthpiece used during breathing exercises to ensure a constant ventilatory flowrate.
Description: women enrolled in WINNER-FLOW-URO-MG group will freely use the expiratory mouthpiece device during all their childbirth process.
Study NCT02950025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online, adaptive MR-guided SBRT
Description: Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day. The estimated delivered dose should be calculated using the software on the console. An adapted radiation therapy plan should be generated
Study NCT03745170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 Q3W on Day 1 by IV infusion
Study NCT02950025 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Online, non-adaptive MR-guided SBRT
Description: Patients will not have online-adaptive treatment planning
Study NCT02950025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: European Organization for Research and Treatment of Cancer (EORTC) QLQ-30
Description: * 30 questions~* 28 questions about various health issues with answers ranging from 1=Not At All to 4 = Very Much~* 1 question asking about overall health with answers ranging from 1=very poor to 7 excellent~* 1 question asking about overall quality of life with answers ranging from 1=very poor to 7=excellent
Study NCT02950025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: European Organization for Research and Treatment of Cancer (EORTC) QLQ-30
Description: * 30 questions~* 28 questions about various health issues with answers ranging from 1=Not At All to 4 = Very Much~* 1 question asking about overall health with answers ranging from 1=very poor to 7 excellent~* 1 question asking about overall quality of life with answers ranging from 1=very poor to 7=excellent
Study NCT01373801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The HemCon GuardaCare
Description: The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.
Study NCT01373801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The HemCon GuardaCare
Description: The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.
Study NCT01373801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard packing gauze roll bandage.
Study NCT00066950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: 0.5oz chlorhexidine gluconate 0.12% solution mouth rinse twice daily for 14 days then no rinse for 14 days, repeated for 3 months
Study NCT00066950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish
Description: 0.25ml FV every 6 months from age 12 to 30 months
Study NCT01442233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plasma exchange
Description: 6 plasma exchange each 48 hours during 2 weeks after randomization
Study NCT01442233 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham exchanges procedure
Description: 6 sham exchanges each 48 hours during 2 weeks after randomization
Study NCT01414114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered 3 times a week by bolus injection into the venous line of the dialysis circuit after the end of hemodialysis.
Study NCT01737944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Vibex MTX Device
Study NCT03745170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m\^2 Q3W on Day 1 by IV infusion
Study NCT03745170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
Study NCT00002925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ara-C
Study NCT00002925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ara-C
Study NCT00002925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Study NCT00002925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Study NCT00002925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Study NCT00002925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT00002925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSC-833
Study NCT00002925 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldesleukin
Study NCT00002925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Study NCT03787953 — intervention group
Intervention type: DRUG
Intervention: Anti-PD-1/PD-L1 antibodies
Description: The study is a real-world study. According to the actual medical history of patients, the usage of anti-PD-1/PD-L1 antibodies was collected.
Study NCT02046356 — intervention group
Intervention type: PROCEDURE
Intervention: MESS-RFA
Study NCT00052208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given PO
Study NCT00052208 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00052208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00818233 — intervention group
Intervention type: DEVICE
Intervention: Dynamic contour tonometry
Description: Observe variability of measurements by dynamic contour tonometry
Study NCT02562430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Welbutrin XL
Description: 12.5% of participants will receive Welbutrin XL in phase 1 of the study.
Study NCT02562430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 87.5% of subjects will be randomized to placebo in phase 1 of the study.
Study NCT04519710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
Description: to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
Study NCT02050360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 40 mg
Study NCT02050360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 80 mg
Study NCT02050360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01545284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin
Description: All patients will receive open-label single oral acitretin 10 mg capsule once daily as a starting dose. If well tolerated, the dose will be increased in the first 4 weeks to a maximum of 30mg/day. Patients will be instructed to take the treatment as a single oral dose with a meal.
Study NCT04528849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin dose increment timing
Description: Gonadotropin dose increments of 25 IU will be utilized on 7th and 14th day of ovulation induction for each study group.
Study NCT03589443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiplexed heptapeptides
Description: Heptapeptides QRH and KSP
Study NCT03745170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
Study NCT03745170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Weight\<60Kg: 3mg/kg Q3W Weignt>=60Kg:200 mg Q3W on Day 1 by IV infusion
Study NCT01244906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
Study NCT02421224 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
Study NCT02421224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deposits
Description: Participants will have to deposit a certain amount of their own money at enrollment. Participants will be able to make additional voluntary deposits above the minimum amount during the intervention period. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.